ArticleApplied biochemistry and biotechnology2025
Nano-engineered Antibiotic Formulation That Targets Chronic MRSA Infection.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The health of millions of people is seriously threatened by infectious diseases that spread rapidly within communities and can lead to outbreaks if not effectively controlled by medical personnel. This study examines the complex mechanisms of antibiotic resistance, specifically focusing on the emergence of methicillin-resistant Staphylococcus aureus (MRSA) and Extended-Spectrum Beta-Lactamase (ESBL)-producing bacteria in Indian healthcare settings. MRSA isolates exhibited complete resistance to ampicillin, ciprofloxacin, amoxicillin, and amoxicillin-clavulanic acid on Mueller-Hinton agar plates. Characterization results indicated an increased inhibition zone diameter and enhanced encapsulation integrity. UV-visible spectrophotometric analysis revealed that ciprofloxacin-loaded liposomes achieved an entrapment efficiency of 16.45% after 1 h, increasing to 76% after 24 h. Encapsulation of ciprofloxacin, amikacin, cloxacillin, and vancomycin within vesicles demonstrated improved antimicrobial efficacy against Escherichia coli, Staphylococcus aureus, Acinetobacter baumannii, Klebsiella pneumoniae, and MRSA. Moreover, liposome-encapsulated aminoglycosides exhibited promising potential against A. baumannii, particularly in localized infections where sustained drug concentrations at the infection site are essential. The results of this study suggest that liposomal antibiotics hold significant potential for treating severe infections both systemically and topically. They may enhance therapeutic effectiveness while minimizing adverse effects, offering a promising approach to combating antibiotic-resistant bacterial infections.
Indexed as
Identifiers
40423746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.